Related Experiment Videos
Donor-specific immunological non-responsiveness after liver transplantation
A P van den Berg1, A de Haan, B G Hepkema
1Department of Gastroenterology and Hepatology, University Hospital, Groningen, The Netherlands. A.P.van.den.Berg@interne.AZG.NL
Summary
Liver transplant recipients often develop non-responsiveness to donor HLA antigens, particularly at the cytotoxic T cell (CTL) level, contributing to long-term graft survival. This immunological adaptation is key to successful liver allograft outcomes.
Area of Science:
- Immunology
- Transplantation Science
- Clinical Medicine
Background:
- Liver allografts exhibit lower immunological loss rates post-transplant compared to other organs.
- Understanding the immune response to donor Human Leukocyte Antigens (HLA) is crucial for long-term graft survival.
Purpose of the Study:
- To investigate the development of immunological non-responsiveness to donor HLA antigens in liver transplant patients with good long-term outcomes.
- To determine if immune tolerance explains the favorable outcomes observed in liver allograft recipients.
Main Methods:
- Assessed immune responses against donor and third-party spleen cells before and 2 years after liver transplantation.
- Measured reactivity using mixed lymphocyte culture (MLC) and quantified cytotoxic T lymphocyte precursor (CTLp) frequencies.
- Evaluated responses against third-party cells to rule out generalized immunosuppression effects.
Main Results:
- Before transplantation, most patients showed normal T cell responses to donor antigens.
- Two years post-transplant, 56% of patients developed donor-specific MLC non-reactivity.
- A significant 83% of patients developed donor-specific cytotoxic T cell (CTL) non-responsiveness.
Conclusions:
- The majority of successful liver transplant recipients develop donor-specific non-responsiveness by 2 years post-transplant.
- This immune tolerance predominantly occurs at the cytotoxic T cell (CTL) level.
- Donor-specific non-responsiveness is a key factor in the favorable long-term outcome of liver allografts.